This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Mesalazine BP Reference standard, intended for use in laboratory tests only as specifically prescribed in the British Pharmacopoeia.
Also used in monographs such as:
Mesalazine Suppositories
Mesalazine Foam Enema
Mesalazine Enema
Mesalazine Prolonged-release Tablets
Mesalazine Gastro-resistant Tablets
Mesalazine Prolonged-release Granules
包装
Unit quantity: 125 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia
Journal of ethnopharmacology, 266, 113394-113394 (2020-09-18)
Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory disease of the gastrointestinal tract, consisting of ulcerative colitis (UC) and Crohn's disease (CD). Gut microbiota and their metabolites may play a role in the pathogen of IBD, especially of